SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that it has initiated studies to test the in vitro effectiveness of the Aethlon Hemopurifier® to capture a partially reconstructed version of the Spanish Flu of 1918, a viral pandemic outbreak that killed approximately 40-50 million people during a 25-month time span. The reconstructed 1918 influenza used in the Hemopurifier® studies is a recombinant virus that has two genes (the HA and NA) from the 1918 strain of influenza along with six genes from the Texas 91 influenza strain. The resulting research virus is known as 1918 HA/NA:TX/36/91.
